Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) are a kind of adult stem cells that can be isolated easily from bone marrow, adipose tissue, umbilical cord and many other tissues. MSCs have been shown to specifically migrate to inflammatory sites, including tumors, and hold great promise as tumor-specific vectors to deliver antitumor agents. Interferon-α (IFNα) has been used in clinic to treat various types of tumors; however, because of its short half-life, significant therapeutic effects require high doses that often results in serious side effects. Here, we tested whether MSCs continuingly secreting IFNα can exert a persistent antitumor effect and eliminate the side effects associated with high clinical doses of recombinant IFNα. We found that even a small number of IFNα-secreting MSCs could potently halt B16 tumor growth in vivo. The antitumor activity of IFNα-secreting MSCs was largely abolished in immunodeficient mice, an effect largely attributed to natural killer cells and CD8(+) T cells. Therefore, IFNα-secreting MSCs provide an innovative strategy for tumor therapy.

Original languageEnglish (US)
Pages (from-to)5047-5052
Number of pages6
JournalOncogene
Volume33
Issue number42
DOIs
StatePublished - Oct 16 2014
Externally publishedYes

Fingerprint

Mesenchymal Stromal Cells
Interferons
Neoplasms
Adult Stem Cells
Umbilical Cord
Therapeutic Uses
Natural Killer Cells
Antineoplastic Agents
Half-Life
Adipose Tissue
Bone Marrow
T-Lymphocytes
Growth

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo. / Xu, C.

In: Oncogene, Vol. 33, No. 42, 16.10.2014, p. 5047-5052.

Research output: Contribution to journalArticle

@article{9dae97de0d8e4854a19b133523619a3b,
title = "Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo",
abstract = "Mesenchymal stem cells (MSCs) are a kind of adult stem cells that can be isolated easily from bone marrow, adipose tissue, umbilical cord and many other tissues. MSCs have been shown to specifically migrate to inflammatory sites, including tumors, and hold great promise as tumor-specific vectors to deliver antitumor agents. Interferon-α (IFNα) has been used in clinic to treat various types of tumors; however, because of its short half-life, significant therapeutic effects require high doses that often results in serious side effects. Here, we tested whether MSCs continuingly secreting IFNα can exert a persistent antitumor effect and eliminate the side effects associated with high clinical doses of recombinant IFNα. We found that even a small number of IFNα-secreting MSCs could potently halt B16 tumor growth in vivo. The antitumor activity of IFNα-secreting MSCs was largely abolished in immunodeficient mice, an effect largely attributed to natural killer cells and CD8(+) T cells. Therefore, IFNα-secreting MSCs provide an innovative strategy for tumor therapy.",
author = "C. Xu",
year = "2014",
month = "10",
day = "16",
doi = "10.1038/onc.2013.458",
language = "English (US)",
volume = "33",
pages = "5047--5052",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "42",

}

TY - JOUR

T1 - Interferon-α-secreting mesenchymal stem cells exert potent antitumor effect in vivo

AU - Xu, C.

PY - 2014/10/16

Y1 - 2014/10/16

N2 - Mesenchymal stem cells (MSCs) are a kind of adult stem cells that can be isolated easily from bone marrow, adipose tissue, umbilical cord and many other tissues. MSCs have been shown to specifically migrate to inflammatory sites, including tumors, and hold great promise as tumor-specific vectors to deliver antitumor agents. Interferon-α (IFNα) has been used in clinic to treat various types of tumors; however, because of its short half-life, significant therapeutic effects require high doses that often results in serious side effects. Here, we tested whether MSCs continuingly secreting IFNα can exert a persistent antitumor effect and eliminate the side effects associated with high clinical doses of recombinant IFNα. We found that even a small number of IFNα-secreting MSCs could potently halt B16 tumor growth in vivo. The antitumor activity of IFNα-secreting MSCs was largely abolished in immunodeficient mice, an effect largely attributed to natural killer cells and CD8(+) T cells. Therefore, IFNα-secreting MSCs provide an innovative strategy for tumor therapy.

AB - Mesenchymal stem cells (MSCs) are a kind of adult stem cells that can be isolated easily from bone marrow, adipose tissue, umbilical cord and many other tissues. MSCs have been shown to specifically migrate to inflammatory sites, including tumors, and hold great promise as tumor-specific vectors to deliver antitumor agents. Interferon-α (IFNα) has been used in clinic to treat various types of tumors; however, because of its short half-life, significant therapeutic effects require high doses that often results in serious side effects. Here, we tested whether MSCs continuingly secreting IFNα can exert a persistent antitumor effect and eliminate the side effects associated with high clinical doses of recombinant IFNα. We found that even a small number of IFNα-secreting MSCs could potently halt B16 tumor growth in vivo. The antitumor activity of IFNα-secreting MSCs was largely abolished in immunodeficient mice, an effect largely attributed to natural killer cells and CD8(+) T cells. Therefore, IFNα-secreting MSCs provide an innovative strategy for tumor therapy.

UR - http://www.scopus.com/inward/record.url?scp=85027953716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027953716&partnerID=8YFLogxK

U2 - 10.1038/onc.2013.458

DO - 10.1038/onc.2013.458

M3 - Article

C2 - 24186200

AN - SCOPUS:85027953716

VL - 33

SP - 5047

EP - 5052

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 42

ER -